IDO1 and B-cell chronic lymphocytic leukemia: As we have observed increased IDO1 expression and kynurenine serum levels in the Eμ-TCL1 mouse model of CLL, we evaluated the therapeutic potential of targeting IDO1 in preclinical treatment studies with two IDO1 inhibitors in mice developing CLL.